Objective:

To evaluate the effect of OTX-TKI on retinal leakage in patients with nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema.

Key Findings:

• OTX-TKI treatment resulted in a general reduction in leakage area and index over 12 months.
• The sham group exhibited an increase in leakage area and index, indicating disease progression.
• Results were consistent across total, peripheral, and posterior pole leakage areas.

Interpretation:

A single injection of OTX-TKI may provide a sustained decrease in retinal leakage, suggesting its potential as a long-acting treatment for diabetic retinopathy.

Limitations:

• The analysis was limited by its small sample size.

Conclusion:

The findings support the use of OTX-TKI as a promising long-term treatment option for diabetic retinopathy, pending further validation in larger studies.